Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 155

Sort by

Sort Order Select

Journal Articles

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML

Blood (2023) 141 (3): 295–308.

https://doi.org/10.1182/blood.2022016916

Published: 2023

Includes: Supplemental data

Journal Articles

Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 5254–5257.

https://doi.org/10.1182/blood-2022-165437

Published: 2022

Journal Articles

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial

Naveen Pemmaraju, Marina Konopleva, Kendra Sweet, Anthony S. Stein, Sumithira Vasu, David A Rizzieri, Eunice S. Wang, Hagop Kantarjian, Christopher L. Brooks, Carole Paley, Tariq I. Mughal, Andrew A. Lane

Blood (2022) 140 (Supplement 1): 6155–6157.

https://doi.org/10.1182/blood-2022-159970

Published: 2022

Journal Articles

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Subanalyses of a Pivotal Trial By Age and Baseline Disease Involvement

Naveen Pemmaraju, Marina Konopleva, Kendra Sweet, Anthony S. Stein, Sumithira Vasu, David A. Rizzieri, Eunice S. Wang, Hagop Kantarjian, Christopher L Brooks, Tariq I. Mughal, Andrew A. Lane

Blood (2021) 138 (Supplement 1): 874.

https://doi.org/10.1182/blood-2021-145109

Published: 2021

Journal Articles

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2021) 138 (Supplement 1): 1284.

https://doi.org/10.1182/blood-2021-146666

Published: 2021

Journal Articles

Allogeneic Stem Cell Transplantation with Omidubicel: Long-Term Follow-up from a Single Center

Chenyu Lin, Laura Morrison, Edwin P. Alyea, III, Taewoong Choi, Cristina Gasparetto, Gwynn D. Long, Richard D. Lopez, David A Rizzieri, Stefanie Sarantopoulos, Anthony D. Sung, Nelson J. Chao, Einat Galamidi-Cohen, Aurelie Schwarzbach, Mitchell E. Horwitz

Blood (2021) 138 (Supplement 1): 1827.

https://doi.org/10.1182/blood-2021-145535

Published: 2021

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL)

Blood (2021) 138 (Supplement 1): 3880.

https://doi.org/10.1182/blood-2021-148652

Published: 2021

Journal Articles

Trial in Progress: A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE ® Antibody Blinatumomab (Blincyto) and Vincristine Sulfate Liposomal Injection (Marqibo) in Adult Subjects with Relapsed/Refractory Philadelphia Negative CD19+ Acute Lymphoblastic Leukemia

David A Rizzieri, Jessica Leonard, Talha Badar, Franklin L. Chen, Bijal D. Shah, Zhiguo Li

Blood (2021) 138 (Supplement 1): 4404.

https://doi.org/10.1182/blood-2021-144548

Published: 2021

Journal Articles

A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2021) 138 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2021-146681

Published: 2021

Journal Articles

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Blood (2021) 138 (Supplement 1): 3134.

https://doi.org/10.1182/blood-2021-147758

Published: 2021

Journal Articles

Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies

Blood (2021) 138 (Supplement 1): 2318.

https://doi.org/10.1182/blood-2021-145344

Published: 2021

Journal Articles

A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy

Lindsay A.M. Rein, MD, David A Rizzieri, MD

Blood (2020) 136 (Supplement 1): 5.

https://doi.org/10.1182/blood-2020-142062

Published: 2020

Journal Articles

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2020) 136 (Supplement 1): 11–13.

https://doi.org/10.1182/blood-2020-139903

Published: 2020

Journal Articles

SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

Stephane De Botton, Thomas Cluzeau, MDPhD, Carlos Enrique Vigil, MD, Rachel J. Cook, MD, Philippe Rousselot, MDPhD, David A Rizzieri, MD, Jane L. Liesveld, MD, Pierre Fenaux, MD PhD, Thorsten Braun, MD PhD, Anne Banos, MD, Michael R. Savona, MD, Don Park, MD, Michael J. Kelly, MD MPH, MS, Angela Volkert, Li Zhou, PhD, Qing Kang-Fortner, PhD, David A. Roth, MD, Eytan M. Stein, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-134600

Published: 2020

Journal Articles

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Eytan M. Stein, MD, Stephane De Botton, Thomas Cluzeau, MDPhD, Arnaud Pigneux, MD PhD, Jane L. Liesveld, MD, Rachel J. Cook, MD, Philippe Rousselot, MDPhD, David A Rizzieri, MD, Thorsten Braun, MD PhD, Dale L. Bixby, MD, Gail J. Roboz, MD, Delphine Lebon, MD, Mael Heiblig, Michael J. Kelly, MD MPH, MS, Angela Volkert, Li Zhou, PhD, Qing Kang-Fortner, PhD, David A. Roth, MD, Pierre Peterlin, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-134602

Published: 2020

Journal Articles

Morphologic Leukemia-Free State in Acute Myeloid Leukemia Is Sufficient for Successful Allogeneic Hematopoietic Stem Cell Transplant

Cindy M. Pabon, MD, Zhiguo Li, PhD, Therese Hennig, PA, Carlos De Castro, Jadee Neff, MD PhD, Mitchell E. Horwitz, MD, Thomas W. Leblanc, Gwynn D. Long, MD, Richard D. Lopez, MD, Anthony D. Sung, MD, Nelson J. Chao, MD MBA, Cristina Gasparetto, MD, Stefanie Sarantopoulos, MD PhD, Donna B. Adams, NP, Harry P. Erba, MD PhD, David A Rizzieri, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-133901

Published: 2020

Journal Articles

Female Gender Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplant

Prioty Islam, MD, Haesu Jin, RN, BSN, BMTCN, Felicia Cao, MD PhD, Lauren M. Bohannon, BS, Yi Ren, MS, Nelson J. Chao, MD MBA, Taewoong Choi, MD, Cristina Gasparetto, MD, Mitchell E. Horwitz, MD, Gwynn D. Long, MD, Richard D. Lopez, MD, David A Rizzieri, MD, Stefanie Sarantopoulos, MD PhD, Anthony D. Sung, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-141151

Published: 2020

Journal Articles

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations

Daniel A. Pollyea, Courtney D. Dinardo, MDMSc, Martha L. Arellano, MD, Arnaud Pigneux, MD PhD, Walter Fiedler, MD, Marina Konopleva, MD PhD, David A Rizzieri, MD, B. Douglas Smith, MD, Atsushi Shinagawa, MD PhD, Roberto M. Lemoli, Monique Dail, PhD, Yinghui Duan, PhD, Brenda J. Chyla, Jalaja Potluri, MD, Jean A Ridgeway, DNP, NP-C, Hagop M. Kantarjian, MD

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-134736

Published: 2020

Journal Articles

The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD

Blood (2020) 136 (1): 130–136.

https://doi.org/10.1182/blood.2019003369

Published: 2020

Includes: Supplemental data

Journal Articles

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Blood (2019) 134 (Supplement_1): 733.

https://doi.org/10.1182/blood-2019-122073

Published: 2019

NARROW

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML

Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Subanalyses of a Pivotal Trial By Age and Baseline Disease Involvement

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Allogeneic Stem Cell Transplantation with Omidubicel: Long-Term Follow-up from a Single Center

Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL)

Trial in Progress: A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE ® Antibody Blinatumomab (Blincyto) and Vincristine Sulfate Liposomal Injection (Marqibo) in Adult Subjects with Relapsed/Refractory Philadelphia Negative CD19+ Acute Lymphoblastic Leukemia

A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies

A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Morphologic Leukemia-Free State in Acute Myeloid Leukemia Is Sufficient for Successful Allogeneic Hematopoietic Stem Cell Transplant

Female Gender Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplant

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations

The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only